The Effect of Chlorpromazine (Largactil®), a Dopamine Receptor Antagonist, on Esophageal Sensitivity in Healthy Volunteers: a Randomized, Double-blind, Placebo-controlled Study.
Trial Snapshot
- Phase
- Not Applicable
- Enrollment
- 14
- Locations
- 1
- Primary Endpoint
- Measurement of changes in esophageal sensitivity after administration of Chlorpromazine
Study Overview
Brief Summary
The effect of chlorpromazine (Largactil) on esophageal sensitivity will be investigated in this study. Overnight fasted subjects will be asked to fill out 2 questionnaires to assess the emotional status before their onset of the stimulation tests. The multimodal stimulation probe will be positioned through the mouth in the distal esophagus.
After the ingestion of the stimulation probe, 10mg of chlorpromazine or placebo (saline) will be slowly administered via intravenous injection. Hereafter the multimodal stimulation tests will be initiated.
Esophageal sensitivity will be assessed by performing thermal, mechanical, electrical and chemical stimulation of the esophagus. The chlorpromazine condition will be compared with a placebo condition, this will be organised on 2 separate study visits in a randomised order.
Detailed Description
INTRODUCTION Gastro-esophageal reflux disease (GERD), defined as the presence of symptoms or lesions that can be attributed to the reflux of gastric contents into the esophagus, is an increasingly prevalent condition in Western societies. The most typical symptoms are heartburn and regurgitation, however GERD can also manifest itself through a variety of esophageal and extra-esophageal symptoms (e.g. chronic cough).
In humans, pain is a multimodal experience composted of sensory, physiological and psychological aspects. In order to mimic the clinical situation, experimental models should be based on multimodal testing regimens in which different receptors and central nervous system mechanisms are activated.
Advances in esophageal sensory stimulation have established that both typical and atypical symptoms may not only arise from acid reflux, but also from reflux events with less acidic pH (pH 4-7). Literature review shows that in GERD patients with persisting symptoms in spite of PPI therapy, ongoing weakly acidic reflux can be considered as an important underlying factor. The basis for symptom generation during weakly-acidic reflux events remains to be determined, but acid sensitivity in the pH range 4-7, mechanical distention (enhanced by air in the refluxate), sensitivity to other chemical factors (e.g. bile salts) and esophageal hypersensitivity to physiological levels of reflux have all been proposed.
Kahrilas et al. described psychogenic factors as an alternative explanation for PPI-refractory symptoms: hyperalgesia, allodynia, hypervigilance, and increased anxiety. Anxiety and depression were found to increase GERD-related symptoms in a population-based study. Patients with a poor reflux-symptom correlation reportedly exhibit a high level of anxiety compared with patients exhibiting good reflux-symptom correlation. In addition, it has been shown that increased levels of anxiety were associated with more severe retrosternal pain and retrosternal burning in GERD patients along with increased levels of anxiety and depression.
The study of the interaction between psychological state and gastrointestinal function is complex. It is known that anxiety is one of the factors affecting visceral sensitivity in humans. The investigators speculate that visceral hypersensitivity plays an important role in symptom perception in refractory GERD. This is suggested by the reflux parameters that are usual within the physiological range during PPI therapy. The investigators previously demonstrated that refractory GERD patients have increased visceral sensitivity for thermal, chemical and mechanical esophageal stimulation compared to healthy subjects.
Study Design
- Study Type
- Interventional
- Allocation
- Randomized
- Intervention Model
- Crossover
- Primary Purpose
- Other
- Masking
- Triple (Participant, Investigator, Outcomes Assessor)
Masking Description
Sessions will run in a double-blind randomized-controlled way. The order of placebo and chlorpromazine administration will be randomized by an online randomization tool (http://www.randomization.com/). The randomization scheme will be carried out by an experienced independent researcher or study nurse, this person will prepare and inject chlorpromazine or placebo. In this way, the investigator performing the actual study and data analysis will be blinded until termination of the study.
Eligibility Criteria
- Ages
- 18 Years to 65 Years (Adult, Older Adult)
- Sex
- All
- Accepts Healthy Volunteers
- Yes
Inclusion Criteria
- •Age between 18 and 60 years old
Exclusion Criteria
- •history of psychiatric disease or a positive first degree psychiatric family history,
- •pregnancy or lactation,
- •concomitant administration of any centrally activating medication or medication affecting esophageal motility,
- •significant co-morbidities (neuromuscular, cardiovascular, pulmonary, endocrine, autoimmune, renal and hepatic),
- •prior history of esophageal, Ear-Nose and Throat or gastric surgery or endoscopic anti- reflux procedure,
- •history of gastrointestinal disease
- •During the last two weeks before the study, the volunteers should be free from medication, except for oral contraceptives.
Arms & Interventions
Chlorpromazine
Administration of an intravenous bolus injection of 10 mg Chlorpromazine to investigate the effect on esophageal sensitivity.
Intervention: Chlorpromazine (Drug)
Chlorpromazine
Administration of an intravenous bolus injection of 10 mg Chlorpromazine to investigate the effect on esophageal sensitivity.
Intervention: Multimodal stimulation probe (Device)
Placebo (Saline)
Administration of an intravenous bolus injection of saline (placebo) as the control condition of chlorpromazine in this cross-over study.
Intervention: Multimodal stimulation probe (Device)
Placebo (Saline)
Administration of an intravenous bolus injection of saline (placebo) as the control condition of chlorpromazine in this cross-over study.
Intervention: Placebo - Concentrate (Drug)
Outcomes
Primary Outcomes
Measurement of changes in esophageal sensitivity after administration of Chlorpromazine
Time Frame: Change in chemical sensitivity between the 2 sessions with at least one week interval, duration of each session: approximately 3 hours. Time frame of the actual chemical stimulation: 30 minutes
Investigation of the effect of chlorpromazine on esophageal sensitivity to multimodal stimulation in a group of healthy volunteers. This will be assessed by comparing the volume of infused acid (volume in mL) of the stimulation tests between the placebo and chlorpromazine condition to see if dopamine antagonism affects sensitivity to acid infusion. Investigation of the effect of chlorpromazine on esophageal sensitivity to multimodal stimulation in a group of healthy volunteers. This will be assessed by comparing the volume of infused acid (ml) of the stimulation tests between the placebo and chlorpromazine condition to see if dopamine antagonism affects sensitivity to increasing intensity of electrical pulses.
Secondary Outcomes
No secondary outcomes reported
